Rafferty Asset Management LLC Has $2.61 Million Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Rafferty Asset Management LLC boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 5.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 57,673 shares of the company’s stock after buying an additional 3,110 shares during the period. Rafferty Asset Management LLC’s holdings in Apogee Therapeutics were worth $2,613,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Optimize Financial Inc acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $203,000. Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth approximately $216,000. BNP Paribas Financial Markets bought a new position in Apogee Therapeutics in the 4th quarter valued at approximately $219,000. Commonwealth Equity Services LLC bought a new position in Apogee Therapeutics in the 4th quarter valued at approximately $222,000. Finally, KLP Kapitalforvaltning AS bought a new position in Apogee Therapeutics in the 4th quarter valued at approximately $226,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Buying and Selling

In other Apogee Therapeutics news, insider Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $35.75, for a total value of $97,418.75. Following the sale, the insider now owns 244,448 shares of the company’s stock, valued at approximately $8,739,016. The trade was a 1.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Thomas Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,175 shares of company stock worth $587,191. 42.77% of the stock is owned by insiders.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE opened at $39.91 on Tuesday. The stock has a market capitalization of $1.84 billion, a P/E ratio of -16.49 and a beta of 1.70. The company has a 50-day moving average price of $36.68 and a 200-day moving average price of $40.91. Apogee Therapeutics, Inc. has a 1 year low of $26.20 and a 1 year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.24. As a group, equities research analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on APGE. Citigroup began coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $95.00 price target for the company. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Wedbush restated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $94.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.